


IN THE CLAIMS:

Please amend the claims as follows.

1 – 3. (Cancelled).

4. (Original) An aporphine compound having the following structure IV:




IV

wherein R₁, R₂, R₅ and R₆ are each selected from H, OH, O-acyl, OMe, OEt, OⁿPr and OⁱPr; R₃ and R₄ are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH₂, NO₂ and CN; and R₇ is selected from H, OH, O-acyl and OMe.

5 – 8. (Cancelled).

9. (Currently Amended) ~~The aporphine compound of claim 1, wherein the aporphine compound is in a~~ A pharmaceutical composition for ~~preventing or~~ treating an ischemic disease that is responsive to an expression level of epithelial nitric oxide synthase (eNOS), wherein the pharmaceutical composition comprises an effective amount of ~~the an~~ aporphine compound having a structure shown in formula (I) below and a pharmaceutically acceptable carrier or excipient[[]],




wherein R₁, R₂, R₆ and R₇ are each selected from H, OH, O-acyl, OMe, OEt, OⁿPr, and

OⁱPr; R₃ and R₅ are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH₂, NO₂ and CN; R₄ is selected from allyl and C_nH_{2n+1}, n ≥ 0; and R₈ is selected from H, OH and OMe.

10 – 11. (Cancelled).


12. (Currently Amended) ~~The aporphine compound of claim 4, wherein the aporphine compound is in a~~ A pharmaceutical composition for preventing or treating an ischemic disease that is responsive to an expression level of epithelial nitric oxide synthase (eNOS), wherein the pharmaceutical composition comprises an effective amount of the an aporphine compound having a structure shown as formula (IV) below and a pharmaceutically acceptable carrier or excipient[[.]],



wherein R₁, R₂, R₅ and R₆ are each selected from H, OH, O-acyl, OMe, OEt, OⁿPr and OⁱPr; R₃ and R₄ are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH₂, NO₂ and CN; and R₇ is selected from H, OH, O-acyl and OMe.

13 – 14. (Cancelled).

15. (Currently Amended) ~~The oxoaporphine compound of claim 7, wherein the oxoaporphine compound is in a~~ A pharmaceutical composition for preventing or treating an ischemic disease that is responsive to an expression level of epithelial nitric oxide synthase (eNOS), wherein the pharmaceutical composition comprises an effective amount of the an aporphine compound having a structure shown as formula (VII) below and a pharmaceutically acceptable carrier or excipient[[.]],



wherein R₁, R₂, R₅ and R₆ are each selected from H, OH, O-acyl, OMe, OEt, OⁿPr and OⁱPr; R₃ and R₄ are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NO₂ and CN; and R₇ is selected from H, OH, O-acyl and OMe.

16. (Cancelled).

17. (New) The pharmaceutical composition of claim 9, wherein the ischemic disease is one of ischemic stroke, ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephalopathy, ischemic cardiac disease, and ischemic enteropathy.

18. (New) The pharmaceutical composition of claim 12, wherein the ischemic disease is one of ischemic stroke, ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephalopathy, ischemic cardiac disease, and ischemic enteropathy.

19. (New) The pharmaceutical composition of claim 15, wherein the ischemic disease is one of ischemic stroke, ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephalopathy, ischemic cardiac disease, and ischemic enteropathy.